Issue 156

US allocates $2 million for psychedelic research into Substance Use Disorder

The US National Institute on Drug Abuse (NIDA) has earmarked $2 million in funding for psychedelic treatment research into Substance Use Disorder (SUD).

NIDA will commit the funds to three to five awards with a budget of $2 million per year. The NIDA Notice of Funding Opportunity has been made available under the UG3/UH3 Phased Innovation Awards Cooperative Agreement.

The funding will go toward research that explores the development of classic psychedelics such as psilocybin and LSD, empathogens like MDMA, dissociatives such as ketamine, and other hallucinogens for the treatment of SUD.

READ MORE

THE FASCINATING WORLD OF FUNCTIONAL MUSHROOMS

There are well over 14,000 species of mushroom-producing fungi that have been identified so far. It is believed that many more exist and have yet to be discovered. In 2017, an article in Microbiology Spectrum estimates that there are between 2.2 and 3.8 million different species of fungi.

Functional mushrooms are a category of mushrooms that have been traditionally used for their health benefits.

Read More

VARIABILITY IN PSYCHEDELIC TREATMENT RESPONSES

New findings on psychedelics will be presented at Neuroscience 2023, the annual meeting of the Society for Neuroscience, on Tuesday, 14 November.

A number of researchers are working with animal models to answer questions about the therapeutic actions of psychedelic compounds, for example, psilocybin treatment had opposite effects on fear extinction learning in male and female rats.

Read More

BUSINESS AND INVESTMENT

Cybin has announced the closing of its underwritten offering of units to one of its largest existing institutional shareholders and new institutional investors for up to $30 million.

Red Light Holland has announced that its psilocybin microdosing capsules, which it aims to distribute in emerging markets, have passed four-month stability testing.

Would your organisation benefit from engaging Europe's psychedelic medicine community?

Partnership with Psychedelic Health provides the opportunity to engage an audience ready to support the development of psychedelic medicine.

For more information and to request the media kit, please email stephanie@psych.global

REQUEST MEDIA KIT

SCIENCE AND RESEARCH

The Atlantic explores the question of whether or not the mental health benefits of psychedelics are linked to their hallucinogenic effects.

A new paper, published in Nature, explores the potential role of “expectations and confirmation bias underlying therapeutic effects of microdosing“.

Colombia University’s Department of Psychiatry explores how psychedelic assisted therapy could provide mental health treatment hope for trans and gender expansive people.

The University of Melbourne has announced a $4.5 million investment in a company developing psychedelic-assisted therapies.

REGULATION AND LEGISLATION

MEPs have called for the EU to support psychedelic research for treating mental health disorders at a Parliamentary meeting on the topic, reports Science Business.

PAREA has launched a policy paper in line with the recent Parliamentary meeting on medical psychedelics in the European Parliament. 

High Times reports that the Massachusetts Governor has unveiled a Veterans Psychedelics Research Bill.

Lexology summarises how Canada, the US and the EU are regulating psychedelic drugs and are allowing them to be used in clinical trials.

ARTICLES OF INTEREST

The Secretary to State has been urged to provide urgent answers on funding for the ‘Right Care, Right Person’ strategy which changes the way emergency services respond to mental health calls.

MEPs have called on the Euopean Commission to prepare a “long-term, comprehensive and integrated EU Mental Health Strategy“, reports European Interest.

Partner with us